Niacin/laropiprant products to be suspended worldwide

The European's Medicines Agency is likely the first of many to propose the suspension of niacin/laropiprant products for dyslipidemia following the failure of the HPS-2 THRIVE trial; Merck confirms it will suspend availability of the medicine where it is available.
Source: theHeart.org - Category: Cardiology Source Type: news